Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies 
Trump Administration Releases New UFO Files and Apollo Mission Records 
France Inflation Rises 2.4% in July as Consumer Prices Increase 
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission 
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Wall Street Hits Record High as Softer Inflation Data Eases Fed Rate Hike Fears 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
US Dollar Slips as Softer PPI Data Eases Fed Rate Hike Expectations 
Pandora Shares Rise as Q2 Results Beat Forecasts, 2026 Outlook Raised 
Gold Prices Slip From 10-Week High as Fed and Hormuz Risks Shape Outlook 
European Stocks Steady as U.S.-Iran War, Euro Zone Data Keep Investors Cautious 
New Mexico Measles Outbreak Cost Reached $5.4 Million, Study Finds 
UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Anthropic Eyes $6B Decart AI Acquisition Ahead of Mega IPO 
Add as a preferred source on Google
Fujirebio Holding is now doubling down on developing blood tests to detect Alzheimer’s against which blockbuster therapy is expected soon.
The tiny Tokyo-based diagnostics firm, a unit of H.U. Group Holdings, which has a market value of $1.2 billion, developed the first US-approved spinal fluid test for Alzheimer’s.
According to Goki Ishikawa, the CEO of Fujirebio, the firm is boosting its lineup of reagents used to detect Alzheimer’s biomarkers in blood tests. It aims to file these tests for approval in the US as early as 2023.
Ishikawa said that the lineups offered by industry leaders are still limited, so they are rushing to create a solid lineup of tests.
